Skip to main content

news

Krishnamurthy & Co (K Law) and Shardul Amarchand Mangaldas have advised biopharmaceutical company Biocon on the $730 million sale of a 15 percent stake in subsidiary Biocon Biologics to Serum Institute of India (SII), which was represented by Veritas Legal.

The deal will grant SII access to 100 million doses of vaccines annually for 15 years.

Biocon Biologics develops affordable biosimilars. SII, the maker of AstraZeneca's COVID-19 shot, which is branded as Covishield in India, is the world's largest vaccine maker.

The deal with SII values Biocon Biologics at about $4.9 billion and will solely focus on COVID-19 vaccines in the initial years, reported Reuters.

Partner Naina Krishna Murthy led the K Law team.

Meanwhile, the SAM team was led by partners Iqbal Khan, Ambarish, Shahana Chatterji, Mukul Baveja, Meghna Rajadhyaksha, Ashoo Gupta, Aparna Mehra and Gauri Chhabra.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

Khaitan, JSA, Hogan Lovells guide $515 mln Waaree IPO

by Nimitt Dixit |

Khaitan & Co has advised Waaree Energies, India's largest manufacturer and exporter of solar modules, on its $515 million initial public offering, with JSA Advocates & Solicitors and Hogan Lovells guiding the bookrunning lead managers.

Deals

CAM, Khaitan guide Adani-backed Renew Exim’s $380 mln ITD acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Adani Group's Dubai-based firm Renew Exim DMCC on its acquisition of a 46.64 percent stake in ITD Cementation India for around $380 million from Italian-Thai Development Public Company, who was represented by Khaitan & Co.

Deals

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.